OptimizeRx names new CFO and CAO, effective January 2027

OptimizeRx Corp. (Nasdaq: OPRX) announced that its board of directors has appointed Andy D'Silva as chief financial officer and Heather Favazza as chief accounting officer, both effective January 1, 2027, according to a company press release.

D'Silva will succeed current CFO Ed Stelmakh, who has held the role for five years. Stelmakh will remain in his current position through December 31, 2026, to facilitate the transition, then serve as a strategic advisor through the end of 2027.

D'Silva most recently served as the company's chief business officer, where he was involved in financial strategy, capital allocation, investor relations, corporate development, and long-range planning.

Favazza has served as the company's corporate controller for eight years. Her responsibilities have included accounting operations, financial reporting, internal controls, and compliance.

"Andy has most recently served as Chief Business Officer and has worked closely with the executive leadership team and the Board on the Company's financial strategy, capital allocation, investor relations, corporate development, and long-range planning," said CEO Silvestro. "His work has been vital to the strong financial foundation we have established, which makes him well-positioned to step into this new role."

The Waltham, Massachusetts-based company said its financial and growth strategy remains unchanged following the leadership transition.

You May Also Be Interested In

• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Faeth Therapeutics names two SVPs ahead of clinical milestones
• Goldman Sachs sees China retail sales growth staying weak